High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population

被引：77
作者：
García-Martín, E
Martínez, C
Ladero, JM
Gamito, FJG
Agúndez, JAG
机构：
[1] Univ Extremadura, Sch Med, Dept Pharmacol, E-06071 Badajoz, Spain
[2] Univ Extremadura, Sch Biol Sci, Dept Biochem, E-06071 Badajoz, Spain
[3] Univ Complutense Madrid, San Carlos Univ Hosp, Serv Gastroenterol, Madrid, Spain
[4] Hosp Insalud, Surg Serv, Merida, Spain
来源：
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 2001年 / 57卷 / 01期
关键词：
CYP2C9; genotype; allele frequency;
D O I：
10.1007/s002280100264
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Objective: To search for ethnic variability in the impact of cytochrome P-450 2C9 (CYP2C9) polymorphism. Methods: CYP2C9 allelic variants related to impaired CYP2C9 metabolism were analysed in genomic DNA from 157 Spanish healthy subjects using amplification-restriction and sequencing procedures. Results: The frequency for CYP2C9 mutated alleles is higher among the Spanish subjects analysed than that reported for other Caucasian individuals: CYP2C9*2. 0.143 and CYP2C9*3, 0.162 (P = 0.0001), Nearly 10% of the individuals studied are expected to metabolise deficiently CYP2C9 substrates. Conclusion: In some Caucasian populations the impact of the CYP2C9 polymorphism may be much higher than that estimated from genotyping studies published to date.
引用
收藏
页码：47 / 49
页数：3
相关论文
共 17 条
[1]   PREVALENCE OF CYP2D6 GENE DUPLICATION AND ITS REPERCUSSION ON THE OXIDATIVE PHENOTYPE IN A WHITE-POPULATION [J].
AGUNDEZ, JAG ;
LEDESMA, MC ;
LADERO, JM ;
BENITEZ, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (03) :265-269
[2]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[3]  
Aynacioglu AS, 1999, BRIT J CLIN PHARMACO, V48, P409
[4]   Allelic and functional variability of cytochrome P4502C9 [J].
Bhasker, CR ;
Miners, JO ;
Coulter, S ;
Birkett, DJ .
PHARMACOGENETICS, 1997, 7 (01) :51-58
[5]  
BULPITT CJ, 1987, LANCET, V1, P494
[6]   The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase [J].
Crespi, CL ;
Miller, VP .
PHARMACOGENETICS, 1997, 7 (03) :203-210
[7]   BIOCHEMISTRY AND MOLECULAR-BIOLOGY OF THE HUMAN CYP2C SUBFAMILY [J].
GOLDSTEIN, JA ;
DEMORAIS, SMF .
PHARMACOGENETICS, 1994, 4 (06) :285-299
[8]   Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms [J].
Haining, RL ;
Hunter, AP ;
Veronese, ME ;
Trager, WF ;
Rettie, AE .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1996, 333 (02) :447-458
[9]   Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment [J].
Ingelman-Sundberg, M ;
Oscarson, M ;
McLellan, RA .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1999, 20 (08) :342-349
[10]   Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations [J].
Inoue, K ;
Yamazaki, H ;
Imiya, K ;
Akasaka, S ;
Guengerich, FP ;
Shimada, T .
PHARMACOGENETICS, 1997, 7 (02) :103-113
12